This IQVIA whitepaper explores how agentic AI is moving from hype to real impact in Asia-Pacific pharma. AI is cutting drug discovery costs by up to 90%, improving trial diversity, boosting regulatory success rates by 20–30%, and predicting supply shortages with 80% accuracy. Companies like Sanofi, Pfizer, and Lilly are using AI for digital twins, rapid molecule design, and AI copilots that save millions of work hours. Challenges remain: data bias, legacy IT, regulatory uncertainty, and a talent gap. Success requires prioritizing high-ROI use cases, building partnerships, and developing AI translators.

Join for free to read